Navigation Links
Novel Compound Shows Promise for Treatment of Alcoholism
Date:9/11/2008

discovery of new therapeutic compounds for treating alcoholism and related disorders."

The Preclinical Development Group that Dr. Bartlett leads at the UCSF-affiliated Gallo Center was established to develop new treatments and bridge the gap between research and clinical treatment. The purpose of the study was to find improved compounds for the treatment of alcoholism. "The study results demonstrate that this compound causes selective and long-lasting reductions of ethanol consumption and suggests the compound might be a promising candidate as a novel treatment for alcoholism. This study indicates that compounds with a higher affinity for delta opioid receptors and reduced affinity for mu opioid receptors might be better treatment candidates than Naltrexone, the current FDA approved treatment for alcoholism", said Dr. Bartlett.

"The study on SoRI-9409 and alcohol cessation has yielded vital data that will help fuel novel treatments for a devastating and very difficult-to-treat illness," said Dr. Bartlett. "To date, we have considered and evaluated other compounds, and theories, but the information yielded from this study, along with previous research on this particular compound, has proven to be the most promising to date. We are looking forward to collaborating with our partner, Southern Research, to enter the next phase of research." The research was also supported by the State of California for Medical Research on Alcohol and Substance Abuse and Department of Defense.

Southern Research operates a successful drug discovery research program resulting in six FDA approved drugs with six additional drug candidates in late-stage preclinical and early clinical development.

"Much of our success stems from having a highly successful medicinal chemistry group, and seeking out collaborators who are driven to help us develop new lead compounds and bring those drugs to market," said David Harris, director of Business Development for the Drug Disco
'/>"/>

SOURCE Southern Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Major State Grant Accelerates Research and Development of Novel Cancer Therapy
2. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
3. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
4. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
5. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
6. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
7. Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
8. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
9. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
10. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 The National Necrotizing Fasciitis Foundation ... has been successfully treated for a life threatening form ... Anibal R. Gauto , Medical Director of Inpatient Wound Care ... Center in Rancho Mirage, California . ... Dr. John Crew at Seton Hospital in ...
(Date:8/20/2014)... , Aug. 20, 2014 Research and Markets ... of Pralmorelin" report to their offering. ... comprehensive data on Pralmorelin globally and regionally ( Europe ... America , Latin America etc.). ... This report focuses on three primary areas; manufacture ...
(Date:8/20/2014)... Research and Markets has ... Wound Care and Closure Market (Types, Applications, End ... Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, ... to their offering. The new ... market (types, applications, end user and geography) - ...
Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Market Report of Pralmorelin 2Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2
(Date:8/20/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... cancer cells grow may help doctors diagnose and treat the ... investigators have found that the deadliest skin cancers occur most ... a long history of sun exposure. These lesions also ... Rapid cell growth -- called "high mitotic rate" -- ...
(Date:8/20/2014)... common approach to treating kidney failure by removing waste ... for people who suddenly developed the condition, in an ... School of Medicine. , Their findings, published online in ... an aggressive method that is standardly used for people ... benefit to the patient. , "Our findings question the ...
(Date:8/20/2014)... NEW YORK, NY (August 20, 2014) Research from ... a critical role in stomach cancer growth and that ... be an effective treatment for the disease. The study ... MD, in collaboration with Duan Chen, MD, PhD, in ... Science Translational Medicine . , "Scientists have long observed ...
(Date:8/20/2014)... 20, 2014 The non-small cell lung ... in the offing across the top 8 developed nations, ... to around USD 8 billion by 2020-end, posting a ... is projected to be driven by innovative therapies entering ... lacking efficient treatment, unlike the non-squamous segment. Thus, patients ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 The main ... 12 per diode panel band perfect spectrum that encompasses the ... most likely to use during photosynthesis. A key point ... is that they almost exclusively reside between 440-480 on the ... the red side of the spectrum. The KIND LED K3 ...
Breaking Medicine News(10 mins):Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2
... ... 18 million Americans suffer from heavy snoring, but don’t realize it,s likely a tell-tale sign ... ... Americans suffer from heavy snoring, but don’t realize it may actually be a tell-tale sign ...
... 16 The 15th Annual National Ergonomics Conference ... - 20, will focus on the importance of workplace ergonomics ... topics of return on investment, the aging workforce, and safety ... offices and call centers, industrial, lab, healthcare, and uncontrolled environments ...
... It was found less effective than extended-release niacin, or ... new study raises more questions about ezetimibe (Zetia), a ... statins to lower LDL, or "bad," cholesterol. , The ... June after it was discovered that LDL-cholesterol-lowering Zetia was ...
... modern medicine finds a way to treat a medical condition, ... also have to find ways to get that treatment into ... research from North Carolina State University shows that much more ... hemophilia patients in the developing world, and that the current ...
... SINGAPORE, Nov. 16 /PRNewswire-Asia/ -- Retail sales ... in the first half of 2009 with,total consumption peaking in ... Contact Lens manufacturers. Positive sales,data showing a growth of 14% ... economic recovery that is being led by consumers spending. , ...
... of ketamine users has been published online today in ... Special K) use increasing faster than any other drug ... showing the consequences of repeated ketamine use provides valuable ... the study, researchers from University College London followed 150 ...
Cached Medicine News:Health News:Heavy Snoring Linked To Potentially Life-Threatening Conditions 2Health News:Heavy Snoring Linked To Potentially Life-Threatening Conditions 3Health News:2009 National Ergonomics Conference Opens in Las Vegas November 17 With Hundreds of Industry Leaders in Attendance 2Health News:Study Raises New Questions About Cholesterol Drug Zetia 2Health News:Study Raises New Questions About Cholesterol Drug Zetia 3Health News:Research highlights need to address hemophilia in developing world 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 3Health News:First ever large-scale study of ketamine users published 2
... UltraClean Agarose, Molecular Biology Grade, ... separation of nucleic acids. It ... DNA fragments from 0.2 to ... UltraClean Agarose is tested and ...
Inquire...
... Agarose 1000 is specifically formulated for high ... fragments <1000 bp. This standard melting temperature ... little as 10 bp difference in size. ... strong gel structure for better handling and ...
High EEO (-mr) (0.23-0.26), suitable for IEP, Gel point (1.5%): 36 1.5 °C Gel strength (1%): > 750 g/cm2....
Medicine Products: